Virgin Coconut Oil supplementation may improve Lipid Profile and Cardiometabolic Risk: Study

Written By :  Dr. Shravani Dali
Published On 2025-12-29 03:30 GMT   |   Update On 2025-12-29 03:31 GMT
Advertisement

Virgin coconut oil (VCO) supplementation may improve certain lipid parameters, especially triglycerides (TG) and HDL cholesterol (HDL-C), but shows limited impact on other cardiometabolic outcomes. Larger, long-term clinical trials are needed to better define its role in cardiometabolic risk management.

Cardiometabolic disorders remain a leading cause of morbidity and mortality worldwide. Virgin coconut oil (VCO), rich in medium-chain triglycerides and phenolic compounds, has been proposed to confer metabolic benefits through lipid modulation, anti-inflammatory activity, and antioxidant effects. However, clinical evidence on its efficacy is mixed. This systematic review and meta-analysis evaluated the impact of VCO on key cardiometabolic risk factors in adults. A comprehensive literature search was conducted in five database from inception to August 2025. RCTs assessing VCO supplementation in adults were included if they reported anthropometric indices, lipid profiles, glycemic markers, blood pressure, or inflammatory outcomes. Data were pooled using a random-effects model.

Advertisement
Results: Fourteen RCTs with 1049 participants from 11 countries, with intervention durations ranging from 2 to 24 weeks, met inclusion criteria. Pooled analyses showed that VCO significantly reduced triglycerides (WMD: − 12.12 mg/dL; 95% CI: − 23.14 to − 1.09) and increased high density lipoprotein-cholesterol (HDL-C) (WMD: 7.91 mg/dL; 95% CI: 4.41 to 11.40). No significant changes were observed for other lipid markers, fasting blood sugar (FBS), anthropometric measures, blood pressure, or CRP. Subgroup analyses indicated greater TG reduction in short-term interventions (≤ 8 weeks) and among individuals with metabolic disorders, and a significant TC increase in participants under 50 years. Assessment of publication bias using funnel plots and Egger’s test indicated no significant evidence of bias.
VCO supplementation may improve specific lipid parameters, particularly TG and HDL-C, while showing limited effects on other cardiometabolic outcomes. Larger, longer-term trials are warranted to clarify its role in cardiometabolic risk management.

Reference:

Zhang, Y., Wang, Y., Li, L. et al. The effect of virgin coconut oil (VCO) on cardiovascular disease risk factors: a systematic review and meta-analysis. Diabetol Metab Syndr 17, 456 (2025). https://doi.org/10.1186/s13098-025-02019-6


Keywords:

Virgin Coconut Oil, supplementation, improve, Lipid Profile, Cardiometabolic Risk, Study, Diabetology & Metabolic Syndrome, Zhang, Y., Wang, Y., Li, L, Virgin coconut oil, Meta-analysis, Triglycerides, HDL cholesterol, Randomized controlled trial




Tags:    
Article Source : Diabetology & Metabolic Syndrome

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News